EUVIMEDEUVIMED entdecken
Fallbericht

Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration

Emi Yamazaki iD, Taku Fujimura iD, Yumi Kambayashi iD, Manami Takahashi-Watanabe iD, Kenta Oka iD, Erika Tamabuchi, Yusuke Muto iD, Akira Hashimoto, Yoshihide Asano iD

The Journal of Dermatology · 2026

DOI: 10.1111/1346-8138.70039 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Emi Yamazaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colitis, Immune Checkpoint Inhibitors, Infliximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have improved melanoma outcomes but can cause severe immune‐related colitis. Infliximab is often used for steroid‐refractory cases, yet its effect on tumor control remains uncertain. We describe three advanced melanoma patients who developed grade 3–4 colitis after nivolumab plus ipilimumab and were treated with infliximab. Although gastrointestinal symptoms improved, all showed rapid disease progression and died within 3–9 months. These cases suggest that infliximab may compromise antitumor immunity in melanoma patients receiving ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColitisImmune Checkpoint InhibitorsInfliximabMelanomaSkin NeoplasmsHumansDisease ProgressionFatal OutcomeIpilimumabNivolumab

Stichwörter der Autor:innen

infliximabirAE colitismelanomanivolumab plus ipilimumab combined therapytumor progression

Substanzen

Immune Checkpoint InhibitorsInfliximabIpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

ORCID-Profile: Emi Yamazaki, Taku Fujimura, Yumi Kambayashi, Manami Takahashi-Watanabe, Kenta Oka, Yusuke Muto, Yoshihide Asano

Zitieren

APA

Yamazaki, E., Fujimura, T., Kambayashi, Y., Takahashi-Watanabe, M., Oka, K., Tamabuchi, E., Muto, Y., Hashimoto, A., & Asano, Y. (2026). Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70039

Vancouver

Yamazaki E, Fujimura T, Kambayashi Y, Takahashi-Watanabe M, Oka K, Tamabuchi E, et al. Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70039

BibTeX
@article{Yamazaki2026,
  author = {Yamazaki, Emi and Fujimura, Taku and Kambayashi, Yumi and Takahashi-Watanabe, Manami and Oka, Kenta and Tamabuchi, Erika and Muto, Yusuke and Hashimoto, Akira and Asano, Yoshihide},
  title = {Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration},
  journal = {The Journal of Dermatology},
  year = {2026},
  doi = {10.1111/1346-8138.70039}
}
Kostenlos starten →